Cue Biopharma Inc Revenu
Quel est le Revenu de Cue Biopharma Inc?
Le Revenu de Cue Biopharma Inc est $8.296M
Quelle est la définition de Revenu?
Le revenu est le revenu qu'une entreprise tire de ses activités commerciales normales, généralement de la vente de biens et de services aux clients.
Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time, as in "Last year, Company X had revenue of $42 million". Profits or net income generally imply total revenue minus total expenses in a given period.
In accounting, revenue is often referred to as the "top line" due to its position on the income statement at the very top. This is to be contrasted with the "bottom line" which denotes net income.
Revenu des entreprises dans Health Care secteur sur NASDAQ par rapport à Cue Biopharma Inc
Que fait Cue Biopharma Inc?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Entreprises avec revenu similaire à Cue Biopharma Inc
- Timah Resources a Revenu de RM8.200M
- Mereo BioPharma plc a Revenu de £8.231M
- CQS New City High Yield Fund a Revenu de £8.238M
- InCity Immobilien AG a Revenu de €8.275M
- Ariadne Australia a Revenu de AUD$8.280M
- Dev Clever Plc a Revenu de £8.284M
- Cue Biopharma Inc a Revenu de $8.296M
- Celldex Therapeutics a Revenu de $8.302M
- RAS Technology Ltd a Revenu de AUD$8.328M
- Motorsport Gaming US a Revenu de $8.352M
- Bitcoin SE a Revenu de €8.360M
- Wey Education Plc a Revenu de £8.364M
- A Toute Vitesse SA a Revenu de €8.370M